Skip to Content

'
Jorge E Romaguera

Present Title & Affiliation

Primary Appointment

Deputy Chairman, Division of Cancer Medicine, Lymphoma/Myeloma Department, Houston, TX
Tenured Professor, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Dual/Joint/Adjunct Appointment

Adjunct Professor, The University of Texas Graduate School of Biomedical Sciences, Houston, TX

Education & Training

Degree-Granting Education

1982 University of Puerto Rico, San Juan, PR, MD, Medical
1978 University of Puerto Rico, San Juan, PR, BS, Biology

Postgraduate Training

1/1988 Fellowship – Hematology (Lymphoma), The University of Texas MD Anderson Cancer Center, Houston, TX
1/1987 Fellowship – Hematology/Oncology, University Hospital, San Juan
1/1985 Straight Internship – Internal Medicine, University Hospital, San Juan

Board Certifications

National Board of Medical Examiners
FLEX
American Board of Internal Medicine (Int.Med.)
American Board of Internal Medicine (Med.Oncol.)

Experience/Service

Academic Appointments

Associate Professor, Department of Lymphoma/Myeloma, University of Texas M.D. Anderson Cancer Center, Houston, TX, 9/1997-2005
Assistant Professor, Department of Hematology, Division Of Medicine, University of Texas M.D. Anderson Cancer Center, Houston, TX, 9/1993-8/1997
Faculty Associate, Department of Lymphoma/Myeloma, Division of Medicine, University of Texas M.D. Anderson Cancer Center,, Houston, TX, 10/1988-9/1993
Instructor, University of Texas Medical School, 8/1988-9/1988

Administrative Appointments/Responsibilities

Fellowship Program Director, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 11/2013-present
Director, Department of Lymphoma/Myeloma, Quality Assurance Program, Houston, TX, 2009-present
Member, Shared Resources Core Matching Committee, Partnership for Excellence in Cancer Research (UT MDACC and University of Puerto Rico), Houston, 2008
Alternate, Department of Lymphoma/Myeloma, Division of Cancer Medicine, CCMS (credentials committee), Houston, TX, 2007-present
Physician Liaison, The University of Texas MD Anderson Cancer Center, Orlando, FL, 2003-2012
Member, Department of Lymphoma/Myeloma, Continuity of Care Committee, Houston, TX, 2002-2009
Telemedicine Program Lymphoma, MDACC Orlando, Orlando, FL, 1998-2012

Military or Other Governmental Service

Department Internal Medicine, Darnall Army Community Hospital, MEDDAC,, Active Duty - U.S. Army-Desert Shield/Desert Storm Operation, Fort Hood, Killeen, TX, 8/1990-5/1991
Major, Medical Corps, U.S. Army Reserve, 4005th USAH, Houston, TX, 10/1988-4/1994
Company B Rank, Captain, Medical Corps, Puerto Rico Army National Guard, 192nd Spt. Bn., 1/1986-9/1988

Institutional Committee Activities

Member, OPPE/FPPE Quality Officers Meeting, 2009-present
Member, MDAPN Quality Management Committee, 2004-2008
Member, Preceptorship Program for Physicians and Pharmacists, 1995-2004

Honors and Awards

2013 Nominee, Award for Excellence in Team Science 2013, MDACC
2009 Eagle Award, Cancer Fighters of Houston
2006-2010 Nominee, Melvin L Samuels Award for Excellence in Patient Care, MDACC

Selected Publications

Peer-Reviewed Original Research Articles

1. Zhou Y, Wang H, Fang W, Romaguera J, Zhang Y, Delasalle K, Kwak LW, Yi Q, Du X, Wang M. Incidence trends of mantle cell lymphoma in the United States between 1975 and 2004. Cancer. In Press.
2. Leventaki V, Manning JT, Luthra R, Mehta P, Oki Y, Romaguera JE, Medeiros LJ, Vega F. Indolent peripheral T-cell lymphoma involving the gastrointestinal tract. Hum Pathol 45(2):421-6, 2/2014. PMID: 24439229.
3. Oki Y, Chuang H, Chasen B, Jessop A, Pan T, Fanale M, Dabaja B, Fowler N, Romaguera J, Fayad L, Hagemeister F, Alma Rodriguez M, Neelapu S, Samaniego F, Kwak L, Younes A. The prognostic value of interim positron emission tomography scan in patients with classical Hodgkin lymphoma. Br J Haematol. e-Pub 1/2014. PMID: 24386943.
4. Oki Y, Buglio D, Fanale M, Fayad L, Copeland A, Romaguera J, Kwak LW, Pro B, de Castro Faria S, Neelapu S, Fowler N, Hagemeister F, Zhang J, Zhou S, Feng L, Younes A. Phase I study of panobinostat plus everolimus in patients with relapsed or refractory lymphoma. Clin Cancer Res 19(24):6882-90, 12/15/2013. e-Pub 10/4/2013. PMID: 24097867.
5. Oki Y, Westin JR, Vega F, Chuang H, Fowler N, Neelapu S, Hagemeister FB, McLaughlin P, Kwak LW, Romaguera JE, Fanale M, Younes A, Rodriguez MA, Orlowski RZ, Wang M, Ouzounian ST, Samaniego F, Fayad L. Prospective phase II study of rituximab with alternating cycles of hyper-CVAD and high-dose methotrexate with cytarabine for young patients with high-risk diffuse large B-cell lymphoma. Br J Haematol 163(5):611-20, 12/2013. e-Pub 10/2013. PMID: 24117234.
6. Wang M, Fowler N, Wagner-Bartak N, Feng L, Romaguera JE, Neelapu SS, Hagemeister F, Fanale M, McLaughlin P, Oki Y, Pro B, Rodriguez MA, Shah J, Thomas S, Younes A, Hosing C, Zhang L, Newberry K, Desai M, Badillo M, Bejarano M, Sun L, Young KH, Samuel C, Hartig K, Chen W, Byrne C, Bell N, Takashida K, Champlin R, Kwak L, Fayad L. Lenalidomide in combination with rituximab for patients with relapsed or refractory diffuse large B cell lymphoma, follicular grade 3 lymphoma, and transformed B cell lymphoma: a phase 2 clinical trial. Leukemia 27(9):1902-1909, 9/2013.
7. Chen Zheng, Pittman E, Romaguera JE, Fayad LE, Wang M, Kwak L, McCarty N. Nuclear translocation of B-cell-specific transcription factor, BACH2, modulates ROS mediated cytotoxic responses in mantle cell lymphoma. Plos One, 9/2013. PMID: 23936317.
8. Wang ML, Rule S, Martin P, Goy A, Auer R, Kahl BS, Jurczak W, Advani RH, Romaguera JE, Williams ME, Barrientos JC, Chmielowska E, Radford J, Stilgenbauer S, Dreyling M, Jedrzejczak WW, Johnson P, Spurgeon SE, Li L, Zhang L, Newberry K, Ou Z, Cheng N, Fang B, McGreivy J, Clow F, Buggy JJ, Chang BY, Beaupre DM, Kunkel LA, Blum KA. Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma. N Engl J Med 369(6):507-16, 8/8/2013. e-Pub 6/19/2013. PMID: 23782157.
9. Nasser QJ, Pfeiffer ML, Romaguera JE, Fowler N, Debnam JM, Samaniego F, El-Sawy T, McLaughlin P, Bakhoum MF, Esmaeli B. Clinical value of magnetic resonance imaging and other baseline testing fo conjunctival mucosa-associated lymphoid tissue lymphoma. Leuk Lymphoma, 8/2013. PMID: 23879202.
10. Desai M, Newberry KJ, Romaguera JE, Zhang L, Ou Z, Wang M. Immunomodulation therapy with lenalidomide in follicular, transformed and diffuse large B cell lymphoma: current data on safety and efficacy. J Hematol Oncol 6(10):1186, 8/2013.
11. Hagemeister F, Rodriguez MA, Deitcher SR, Younes A, Fayad LE, Goy A, Dang NH, Forman A, McLaughlin P, Medeiros LJ, Pro B, Romaguera JE, Samaniego F, Silverman JA, Sarris A, Cabanillas F. Long term results of a phase 2 study of vincristine sulfate liposome injection (marqibo) substituted for non-liposomal vincristine in CHOP with or without rituximab for patients with untreated aggressive non-hodgkin's lymphomas. Br J Haematol, 6/2013. e-Pub 6/2013. PMID: 23802738.
12. Streckfus CF, Romaguera JE, Guajardo-Streckfus C. The use of salivary protein secretions as an in vivo model to study mantel cell lymphoma progression and treatment. Cancer Invest(31):494-499, 6/2013.
13. Oki Y, Younes A, Copeland A, Hagemeister F, Fayad LE, McLaughlin P, Shah J, Fowler N, Romaguera J, Kwak LW, Pro B. Phase I study of vorinostat in combination with standard CHOP in patients with newly diagnosed peripheral T-cell lymphoma. Br J Haematol. e-Pub 4/17/2013. PMID: 23590726.
14. Wang M, Fowler N, Wagner-Bartak N, Feng L, Romaguera JE, Neelapu SS, Hagemeister F, Fanale M, Oki Y, Pro B, Shah J, Thomas S, Younes A, Hosing C, Zhang L, Newberry KJ, Desai M, Cheng N, Badillo M, Bejarano M, Chen Y, Young KH, Chamlin R, Kwak L, Fayad L. Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular, and transformed lymphoma: a phase II clinical trial. Leukemia, 4/2013. PMID: 23545991.
15. Westin JR, Thompson MA, Cataldo VD, Fayad LE, Fowler N, Fanale MA, Neelapu S, Samaniego F, Romaguera J, Shah J, McLaughlin P, Pro B, Kwak LW, Sanjorjo P, Murphy WA, Jimenez C, Toth B, Dong W, Hagemeister FB. Zoledronic Acid for Prevention of Bone Loss in Patients Receiving Primary Therapy for Lymphomas: A Prospective, Randomized Controlled Phase III Trial. Clin Lymphoma Myeloma Leuk 13(2):99-105, 4/2013. e-Pub 12/29/2012. PMID: 23276888.
16. Batty N, Ghonimi E, Feng L, Fayad L, Younes A, Rodriguez MA, Romaguera JE, McLaughlin P, Samaniego F, Kwak LW, Hagemeister FB. The Absolute Monocyte and Lymphocyte Prognostic Index for Patients With Diffuse Large B-Cell Lymphoma Who Receive R-CHOP. Clin Lymphoma Myeloma Leuk 13(1):15-8, 2/2013. e-Pub 11/6/2012. PMID: 23137719.
17. Younes A, Romaguera J, Fanale M, McLaughlin P, Hagemeister F, Copeland A, Neelapu S, Kwak L, Shah J, de Castro Faria S, Hart S, Wood J, Jayaraman R, Ethirajulu K, Zhu J. Phase I Study of a Novel Oral Janus Kinase 2 Inhibitor, SB1518, in Patients With Relapsed Lymphoma: Evidence of Clinical and Biologic Activity in Multiple Lymphoma Subtypes. J Clin Oncol 30(33):4161-7, 11/20/2012. e-Pub 9/10/2012. PMID: 22965964.
18. Zhang L, Yang J, Qian J, Li H, Romaguera JE, Kwak LW, Wang M, Yi Q. Role of the microenvironment in mantle cell lymphoma: IL-6 is an important survival factor for the tumor cells. Blood 120(18):3783-92, 11/1/2012. e-Pub 9/11/2012. PMCID: PMC3488890.
19. Chen Z, Romaguera J, Wang M, Fayad L, Kwak LW, McCarty N. Verapamil synergistically enhances cytotoxicity of bortezomib in mantle cell lymphoma via induction of reactive oxygen species production. Br J Haematol 159(2):243-6, 10/2012. e-Pub 8/24/2012. PMCID: PMC3460105.
20. Younes A, Kim S, Romaguera J, Copeland A, Farial Sde C, Kwak LW, Fayad L, Hagemeister F, Fanale M, Neelapu S, Lambert JM, Morariu-Zamfir R, Payrard S, Gordon LI. Phase I multi-dose escalation study of the anti-CD19 maytansinoid immunoconjugate SAR3419 administered by intravenous infusione very 3 weeks to patients with relapsed/refractory B-cell lymphoma. J Clin Oncol 30(22):2776-82, 8/1/2012. e-Pub 7/2/2012. PMID: 22753910.
21. Weng J, Rawal S, Chu F, Park HJ, Sharma R, Delgado DA, Fayad L, Fanale M, Romaguera J, Luong A, Kwak LW, Neelapu SS. TCL1: a shared tumor-associated antigen for immunotherapy against B-cell lymphomas. Blood 120(8):1613-23, 8/23/2012. e-Pub 5/29/2012. PMCID: PMC3429305.
22. Wang M, Fayad L, Wagner-Bartak N, Zhang L, Hagemeister F, Neelapu SS, Samaniego F, McLaughlin P, Fanale M, Younes A, Cabanillas F, Fowler N, Newberry KJ, Sun L, Young KH, Champlin R, Kwak L, Feng L, Badillo M, Bejarano M, Hartig K, Chen W, Chen Y, Byrne C, Bell N, Zeldis J, Romaguera J. Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial. Lancet Oncol 13(7):716-23, 7/2012. e-Pub 6/2012. PMID: 22677155.
23. Younes A, Oki Y, McLaughlin P, Copeland AR, Goy A, Pro B, Feng L, Yuan Y, Chuang HH, Macapinlac HA, Hagemeister F, Romaguera J, Samaniego F, Fanale MA, Dabaja BS, Rodriguez MA, Dang N, Kwak LW, Neelapu SS, Fayad LE. Phase II study of rituximab plus ABVD in patients with newly diagnosed classical Hodgkin lymphoma. Blood 119(18):4123-8, 5/3/2012. e-Pub 2/27/2012. PMCID: PMC3359733.
24. Oki Y, Copeland A, Romaguera J, Fayad L, Fanale M, Faria Sde C, Medeiros LJ, Ivy P, Younes A. Clinical Experience with the Heat Shock Protein-90 inhibitor, Tanespimycin (17AAG), in Patients with Relapsed Lymphoma. Leuk Lymphoma 53(5):990-2, 5/2012. e-Pub 3/13/2012. PMID: 21988665.
25. Batty N, Hagemeister FB, Feng L, Romaguera JE, Rodriguez MA, McLaughlin P, Samaniego F, Copeland A, Dabaja BS, Younes A. Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine Chemotherapy with Interferon for Advanced Stage Classic Hodgkin's Lymphoma: A 10-Year Follow-up Study. Leuk Lymphoma 53(5):801-6, 5/2012. e-Pub 1/3/2012. PMID: 22023528.
26. Liu W, Medeiros LJ, Lin P, Romaguera JE, Wang SA, Jorgensen JL. Usefulness of flow cytometric immunophenotyping for bone marrow staging in patients with mantle cell lymphoma after therapy. Am J Clin Pathol 137(4):634-40, 4/2012. PMID: 22431541.
27. Wei L, Medeiros J, Wang S, Romaguera JE. Utility of flow cytometric immunophenotyping for bone marrow staging of patients with mantle cell lymphoma after therapy. Am J Clin Pathol 137(4):634-640, 4/2012.
28. Jung HJ, Chen Z, Wang M, Fayad L, Romaguera J, Kwak LW, McCarty N. Calcium blockers decrease the bortezomib resistance in mantle cell lymphoma (MCL) via manipulation of tissue transglutaminase activities. Blood 119(11):2568-78, 3/15/2012. e-Pub 1/31/2012. PMID: 22294726.
29. Oki Y, Copeland A, Hagemeister F, Fayad LE, Fanale M, Romaguera J, Younes A. Experience with obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist in patients with relapsed or refractory classical Hodgkin lymphoma. Blood 119(9):2171-2, 3/1/2012. PMID: 22383790.
30. Jung HJ, Chen Z, Fayad L, Wang M, Romaguera J, Kwak LW, McCarty N. Bortezomib-resistant nuclear factor κB expression in stem-like cells in mantle cell lymphoma. Exp Hematol 40(2):107-18.e2, 2/2012. e-Pub 10/21/2011. PMID: 22024108.
31. Shah N, Cabanillas F, McIntyre B, Feng L, McLaughlin P, Rodriguez MA, Romaguera J, Younes A, Hagemeister FB, Kwak L, Fayad L. Prognostic value of serum CD44, ICAM-1 and VCAM-1 levels in patients with indolent non-Hodgkin lymphomas. Leuk Lymphoma 53(1):50-6, 1/2012. e-Pub 10/24/2011. PMID: 21895545.
32. Jones RJ, Baladandayuthapani V, Neelapu S, Fayad LE, Romaguera JE, Wang M, Sharma R, Yang D, Orlowski RZ. HDM-2 inhibition suppresses expression of ribonucleotide reductase subunit M2, and synergistically enhances gemcitabine-induced cytotoxicity in mantle cell lymphoma. Blood 118(15):4140-9, 10/13/2011. e-Pub 8/15/2011. PMID: 21844567.
33. Vadhan-Raj S, Fayad LE, Fanale MA, Pro B, Rodriguez A, Hagemeister FB, Bueso-Ramos CE, Zhou X, McLaughlin PW, Fowler N, Shah J, Orlowski RZ, Samaniego F, Wang M, Cortes JE, Younes A, Kwak LW, Sarlis NJ, Romaguera JE. A randomized trial of a single-dose rasburicase versus five-daily doses in patients at risk for tumor lysis syndrome. Ann Oncol 10. e-Pub 10/2011. PMID: 22015451.
34. Srokowski TP, Liebmann JE, Modiano MR, Cohen GI, Pro B, Romaguera JE, Kuepfer C, Singer JW, Fayad LE. Pixantrone dimaleate in combination with fludarabine, dexamethasone, and rituximab in patients with relapsed or refractory indolent non-Hodgkin lymphoma: Phase 1 Study With a Dose-Expansion Cohort. Cancer. e-Pub 6/2011. PMID: 21681734.
35. Thomas DA, O'Brien S, Faderl S, Manning JT, Romaguera J, Fayad L, Hagemeister F, Medeiros J, Cortes J, Kantarjian H. Burkitt lymphoma and atypical Burkitt or Burkitt-like lymphoma: should these be treated as different diseases? Curr Hematol Malig Rep 6(1):58-66, 3/2011. PMID: 21191675.
36. Chen Z, Ayala P, Wang M, Fayad L, Katz RL, Romaguera J, Caraway N, Neelapu SS, Kwak LW, Simmons PJ, McCarty N. Prospective isolation of clonogenic mantle cell lymphoma-initiating cells. Stem Cell Res 5(3):212-25, 11/2010. e-Pub 8/6/2010. PMCID: PMC2952723.
37. Romaguera JE, Fayad LE, McLaughlin P, Pro B, Rodriguez A, Wang M, Weaver P, Hartig K, Kwak LW, Feldman T, Smith J, Ford P, Goldberg S, Pecora A, Goy A. Phase I trial of bortezomib in combination with rituximab-hyperCVAD alternating with rituximab, methotrexate and cytarabine for untreated aggressive mantle cell lymphoma. Br J Haematol 151(1):47-53, 10/2010. e-Pub 8/2010. PMID: 20735402.
38. Romaguera JE, Fayad LE, Feng L, Hartig K, Weaver P, Rodriguez MA, Hagemeister FB, Pro B, McLaughlin P, Younes A, Samaniego F, Goy A, Cabanillas F, Kantarjian H, Kwak L, Wang M. Ten-year follow-up after intense chemoimmunotherapy with Rituximab-HyperCVAD alternating with Rituximab-high dose methotrexate/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma. Br J Haematol 150(2):200-8, 7/2010. e-Pub 5/2010. PMID: 20528872.
39. Gupta S, Sultenfuss M, Romaguera JE, Ensor J, Krishnamurthy S, Wallace MJ, Ahrar K, Madoff DC, Murthy R, Hicks ME. CT-guided percutaneous lung biopsies in patients with haematologic malignancies and undiagnosed pulmonary lesions. Hematol Oncol 28(2):75-81, 6/2010. e-Pub 9/2009. PMID: 19728397.
40. Tomas JF, Dang J, Pro B, Rodriguez MA, McLaughlin P, Romaguera JE, Younes A, Hagemeister F, Cabanillas F, Podoloff D, Fayad LE. El tamizaje con galio despues del segundo y cuarto ciclos de uimioterapia es predictor de linfomas no Hodgkin. Revista de Hematol 11:5-14, 3/2010.
41. Dabaja B, Perrin KJ, Romaguera JE, Horace P, Wogan CF, Shihadeh F, Salehpour MR. Successful treatment of a free-moving abdominal mass with radiation therapy guided by cone-beam computed tomography: a case report. J Med Case Reports 4:329, 2010. e-Pub 10/2010. PMCID: PMC2974745.
42. Wang M, Oki Y, Pro B, Romaguera JE, Rodriguez MA, Samaniego F, McLaughlin P, Hagemeister F, Neelapu S, Copeland A, Samuels BI, Loyer EM, Ji Y, Younes A. Phase II study of yttrium-90-ibritumomab tiuxetan in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol 27(31):5213-8, 11/2009. e-Pub 9/2009. PMID: 19770379.
43. Inamdar KV, Romaguera JE, Drakos E, Knoblock RJ, Garcia M, Leventaki V, Medeiros LJ, Rassidakis GZ. Expression of Eukaryotic Initiation Factor 4E Predicts Clinical Outcome in Patients with Mantle Cell Lymphoma Treated with Hyper-CVAD and Rituximab, Alternating with Rituximab, High-Dose Methotrexate, and Cytarabine. Cancer 115(20):4727-36, 10/2009. PMID: 19708031.
44. Hess G, Herbrecht R, Romaguera J, Verhoef G, Crump M, Gisselbrecht C, Laurell A, Offner F, Strahs A, Berkenblit A, Hanushevsky O, Clancy J, Hewes B, Moore L, Coiffier B. Phase III Study to Evaluate Temsirolimus Compared With Investigator's Choice Therapy for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma. J Clin Oncol 27(23):3822-9, 8/2009. e-Pub 7/2009. PMID: 19581539.
45. Zhou Y, Garcia MK, Chang DZ, Chiang J, Lu J, Yi Q, Romaguera J, Delasalle K, Guo Y, Forman A, Fang W, Wang M. Multiple myeloma, painful neuropathy, acupuncture? Am J Clin Oncol 32(3):319-25, 6/2009. PMID: 19887992.
46. Esmaeli B, McLaughlin P, Pro B, Samaniego F, Gayed I, Hagemeister F, Romaguera J, Cabanillas F, Neelapu S, Banay R, Fayad L, Seveille W, Kwak L. Prospective trial of targeted radioimmunotherapy with Y-90 ibritumomab tiuxetan (zevalin) for front-line treatment of early-stage extranodal indolent ocular adnexal lymphoma. J Clin Oncol 20(4):709-14, 4/2009.
47. Garcia M, Romaguera JE, Inamdar KV, Rassidakis GZ, Medeiros LJ. Proliferation predicts failure-free survival in mantle cell lymphoma patients treated with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with rituximab plus high-dose methotrexate and cytarabine. Cancer 115(5):1041-8, 3/2009. PMID: 19170236.
48. Wang M, Fayad L, Cabanillas F, Hagemeister F, McLaughlin P, Rodriguez MA, Kwak LW, Zhou Y, Kantarjian H, Romaguera J. Phase 2 trial of rituximab plus hyper-CVAD alternating with rituximab plus methotrexate-cytarabine for relapsed or refractory aggressive mantle cell lymphoma. Cancer 113(10):2734-41, 11/2008. PMID: 18973182.
49. Shah JJ, Fayad L, Romaguera J. Mantle Cell International Prognostic Index (MIPI) Not Prognostic After R-HCVAD. Blood 112(6):2583, Sept 15 2008, 9/2008.
50. Pro B, Leber B, Smith M, Fayad L, Romaguera J, Hagemeister F, Rodriguez A, McLaughlin P, Samaniego F, Zwiebel J, Lopez A, Kwak L, Younes A. Phase II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in combination with rituximab in patients with recurrent B-cell non-Hodgkin lymphoma. Br J Haematol 143(3):355-60, 9/2008. e-Pub 9/2008. PMID: 18764869.
51. Wang M, Zhang L, Han X, Yang J, Qian J, Hong S, Lin P, Shi Y, Romaguera J, Kwak LW, Yi Q. A Severe Combined Immunodeficient-hu In vivo Mouse Model of Human Primary Mantle Cell Lymphoma. Clin Cancer Res 14(7):2154-2160, 4/2008. PMID: 18381957.
52. Yazbeck VY, Buglio D, Georgakis GV, Li Y, Iwado E, Romaguera JE, Kondo S, Younes A. Temsirolimus downregulates p21 without altering cyclin D1 expression and induces autophagy and synergizes with vorinostat in mantle cell lymphoma. Exp Hematol 36(4):443-50, 4/2008. PMID: 18343280.
53. Overman MJ, Feng L, Pro B, McLaughlin P, Hess M, Samaniego F, Younes A, Romaguera JE, Hagemeister FB, Kwak L, Cabanillas F, Rodriguez MA, Fayad LE. The additionof rituximab to CHOP chemotherapy improves overall and failure-free survival for follicular grade 3 lymphoma. Ann Oncol 19(3):553-9, 3/2008. PMID: 18083690.
54. Anderlini P; Saliba R; Acholonu S; Giralt SA; Andersson B; Ueno NT; Hosing C; Khouri IF; Coureil d; de Lima M; Qazilbash MH; Pro B; Romaguera J; Fayad L; Hagemeister F; Younes A; Munsell MF; champlin RE. Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin's lymphoma: the updated M.D. Anderson Cancer Center experience. Haematologica 93(2):257-64, 2/2008. e-Pub 1/2008. PMID: 18223284.
55. Zhou Y; Zhang L; Romaguera J; Delasalle K; Han X; Du X; Kwak L; Yi Q; Wang M. Immunotherapy in mantle cell lymphoma: anti-CD20-based therapy and beyond. Am J Hematol 83(2):144-9, 2/2008. PMID: 17722077.
56. Oki Y; Pro B; Fayad LE; Romaguera J; Samaniego F; Hagemeister F; Neelapu S; McLaughlin P; Goy A; Younes A. Phase 2 study of gemcitabine in combination with rituximab in patients with recurrent or refractory Hodgkin lymphoma. Cancer 112(4):831-6, 2/2008. PMID: 18085611.
57. Wang, M; Han XH; Zhang L; Yang J; Qian JF; Shi YK; Kwak LW; Romaguera J; Yi Q. Bortezomib is synergistic with rituximab and cyclophosphamide in inducing apoptosis of mantle cell lymphoma cells in vitro and in vivo. Leukemia 22(1):17-185, 1/2008.
58. Esmaeli B, McLaughlin P, Pro B, Samaniego F, Gayed I, Hagemeister F, Romaguera J, Cabanillas F, Neelapu S, Banay R, Fayad L, Seville W, Kwak L. Zevalin for orbital lymphoma paper. Journal of Clinical Oncology, 1/2008.
59. Romaguera JE. Mantle Cell Lymphoma: Frontline and Salvage Therapy. Current Hematologic Malignancy Reports 3(4):204-209, 2008.
60. Fayad L, Thomas D, Romaguera J. Update of the M. D. Anderson Cancer Center experience with hyper-CVAD and rituximab for the treatment of mantle cell and Burkitt-type lymphomas. Clin Lymphoma Myeloma Suppl 2:S57-62, 12/2007. PMID: 18284717.
61. Soriano AO, Thompson MA, Admirand JH, Fayad LE, Rodriguez AM, Romaguera JE, Hagemeister FB, Pro B. Follicular Dendritic Cell Sarcoma: A Report of 14 Cases and a Review of the Literature. Am J Hematol 82(8):725-8, 8/2007. PMID: 17373675.
62. Iwuanyanwu E, Medeiros LJ, Romaguera J, Fayad LE. Mantle cell lymphoma with a rare involvement of the testicle. Leuk Lymphoma 48(6):1242-3, 6/2007. PMID: 17577795.
63. Dang NH, Pro B, Hagemeister FB, Samaniego F, Jones D, Samuels BI, Rodriguez MA, Goy A, Romaguera JE, McLaughlin P, Tong AT, Turturro F, Walker PL, Fayad L. Phase II trial of denileukin diftitox for relapsed/refractory T-cell non-Hodgkin lymphoma. Br J Haematol 136(3):439-47, 2/2007.
64. Dang NH, Fayad L, McLaughlin P, Romaguera JE, Hagemeister FB, Goy A, Neelapu S, Samaniego F, Walker PL, Wang M, Rodriguez MA, Tong AT, Pro B. Phase II trial of the combination of denileukin diftitox and rituximab for relapsed/refractory B-cell non-Hodgkin’s lymphoma. Br J Haematol 138:502-05, 2007.
65. Safdar A, Rodriguez MA, Fayad LE, Rodriguez GH, Pro B, Wang M, Romaguera JE, Goy AH, Hagemeister FB, McLaughlin P, Bodey GP, Kwak LW, Raad II, Couch RB. Dose-related safety and immunogenicity of baculovirus-expressed trivalent influenza vaccine: a double-blind, controlled trial in adult patients with non-Hodgkin B cell lymphoma. J Infect Dis 194(10):1394-7, 11/15/2006. e-Pub 10/6/2006. PMID: 17054068.
66. Younes A, Fayad L, Romaguera JE, Pro B, Goy A, Wang M,. Safety and efficacy of once-per-cycle pegfilgrastim in support of ABVD chemotherapy in patients with Hodgkin lymphoma. Eur J Cancer 42(17):2976-81, 11/2006. e-Pub 9/27/2006. PMID: 17008093.
67. Wedgwood A, Medeiros LJ, Romaguera JE. CD20+ nodal marginal zone B-cell lymphoma with CD20-recurrence as an intracranial dural-based mass. Leuk Lymphoma 47(10):2253-6, 10/2006. PMID: 17071504.
68. Pro B, Hagemeister FB, McLaughlin P, Romaguera JE, Rodriguez MA, Cabanillas F, Tiongson LP, Younes. Phase 2 study of fludarabine and paclitaxel in patients with recurrent low-grade non-Hodgkin’s lymphoma. Leuk Lymphoma 47(9):1818-21, 9/2006.
69. Wang M, Zhou Y, Zhang L, Nguyen CA, Romaguera J. Use of bortezomib in B-cell non-Hodgkin's lymphoma. Expert Rev Anticancer Ther 6(7):983-91, 7/2006. PMID: 16831071.
70. Liu Q, Fayad L, Cabanillas F, Hagemeister FB, Ayers GD, Hess M, Romaguera J, Rodriguez MA, Tsimberidou AM, Verstovsek S, Younes A, Pro B, Lee MS, Ayala A, McLaughlin P. Improvement of overall and failure-free survival in stage IV follicular lymphoma: 25 years of treatment experience at The University of Texas M.D. Anderson Cancer Center. J Clin Oncol 24(10):1582-9, 4/2006. PMID: 16575009.
71. Pro B, Fayad L, McLaughlin P, Romaguera J, Hagemeister FB, Rodriguez MA, Goy A, Loyer E, Younes A. Pegfilgrastim administered in a single fixed dose is effective in inducing neutrophil count recovery after paclitaxel and topotecan chemotherapy in patients with relapsed aggressive non-Hodgkin's lymphoma. Leuk Lymphoma 47(3):481-5, 3/2006. PMID: 16396772.
72. Romaguera JE, Fayad L, Rodriguez MA, Broglio KR, Hagemeister FB, Pro B, McLaughlin P, Younes A, Samaniego F, Goy A, Sarris AH, Dang NH, Wang M, Beasley V, Medeiros LJ, Katz RL, Gagneja H, Samuels BI, Smith TL, Cabanillas FF. High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. J Clin Oncol 23(28):7013-23, 10/2005. e-Pub 9/6/2005. PMID: 16145068.
73. Ha CS, Cabanillas F, Lee MS, Tucker SL, McLaughlin P, Rodriguez MA, Younes A, Romaguera JE, Mesina OM, Cox JD. A prospective randomized study to compare the molecular response rates between central lymphatic irradiation and intensive alternating triple chemotherapy in the treatment of stage I-III follicular lymphoma. Int J Radiat Oncol Biol Phys 63(1):188-93, 9/2005. PMID: 16111588.
74. Tsimberidou AM, Younes A, Romaguera J, Hagemeister FB, Rodriguez MA, Feng L, Ayala A, Smith TL, Cabanillas F, McLaughlin P. Immunosuppression and infectious complications in patients with stage IV indolent lymphoma treated with a fludarabine, mitoxantrone, and dexamethasone regimen. Cancer 104(2):345-53, 7/2005. PMID: 15948158.
75. McLaughlin P, Estey E, Glassman A, Romaguera J, Samaniego F, Ayala A, Hayes K, Maddox AM, Preti HA, Hagemeister FB. Myelodysplasia and acute myeloid leukemia following therapy for indolent lymphoma with fludarabine, mitoxantrone, and dexamethasone (FND) plus rituximab and interferon alpha. Blood 105(12):4573-5, 6/2005. e-Pub 3/1/2005. PMCID: PMC1895007.
76. Anderlini P, Saliba R, Acholonu S, Okoroji GJ, Donato M, Giralt S, Andersson B, Ueno NT, Khouri I, De Lima M, Hosing C, Cohen A, Ippoliti C, Romaguera J, Rodriguez MA, Pro B, Fayad L, Goy A, Younes A, Champlin RE. Reduced-intensity allogeneic stem cell transplantation in relapsed and refractory Hodgkin's disease: low transplant-related mortality and impact of intensity of conditioning regimen. Bone Marrow Transplant 35:943-51, 5/2005. PMID: 15806128.
77. Caraway NP, Gu J, Lin P, Romaguera JE, Glassman A, Katz R. The utility of interphase fluorescence in situ hybridization for the detection of the translocation t(11;14)(q13;q32) in the diagnosis of mantle cell lymphoma on fine-needle aspiration specimens. Cancer 105(2):110-8, 4/2005. PMID: 15712276.
78. Goy A, Younes A, McLaughlin P, Pro B, Romaguera JE, Hagemeister F, Fayad L, Dang NH, Samaniego F, Wang M, Broglio K, Samuels B, Gilles F, Sarris AH, Hart S, Trehu E, Schenkein D, Cabanillas F, Rodriguez AM. Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol 23(4):667-75, 2/2005. e-Pub 12/21/2004. PMID: 15613697.
79. Romaguera JE, Hagemeister FB. Lymphoma of the colon. Curr Opin Gastroenterol 21:80-84, 2005.
80. Dang NH, Hagemeister FB, Pro B, McLaughlin P, Romaguera JE, Jones D, Samuels B, Samaniego F, Younes A, Wang M, Goy A, Rodriguez MA, Walker PL, Arredondo Y, Tong AT, Fayad L. Phase II study of denileukin diftitox for relapsed/refractory B-Cell non-Hodgkin's lymphoma. J Clin Oncol 22(20):4095-102, 10/2004. e-Pub 9/7/2004. PMID: 15353540.
81. Younes A, Pro B, Robertson MJ, Flinn IW, Romaguera JE, Hagemeister F, Dang NH, Fiumara P, Loyer EM, Cabanillas FF, McLaughlin PW, Rodriguez MA, Samaniego F. Phase II clinical trial of interleukin-12 in patients with relapsed and refractory non-Hodgkin's lymphoma and Hodgkin's disease. Clin Cancer Res 10(16):5432-8, 8/2004. PMID: 15328181.
82. Gu J, Huh YO, Jiang F, Caraway NP, Romaguera JE, Zaidi TM, Fernandez RL, Zhang H, Khouri IF, Katz RL. Evaluation of peripheral blood involvement of mantle cell lymphoma by fluorescence in situ hybridization in comparison with immunophenotypic and morphologic findings. Mod Pathol 17(5):553-60, 5/2004. PMID: 15001994.
83. Popat U, Hosing C, Saliba RM, Anderlini P, van Besien K, Przepiorka D, Khouri IF, Gajewski J, Claxton D, Giralt S, Rodriguez M, Romaguera J, Hagemeister F, Ha C, Cox J, Cabanillas F, Andersson BS, Champlin RE. Prognostic factors for disease progression after high-dose chemotherapy and autologous hematopoietic stem cell transplantation for recurrent or refractory Hodgkin's lymphoma. Bone Marrow Transplant 33:1015-23, 5/2004. PMID: 15048145.
84. Pro B, Younes A, Albitar M, Dang NH, Samaniego F, Romaguera J, McLaughlin P, Hagemeister FB, Rodriguez MA, Clemons M, Cabanillas F. Thalidomide for patients with recurrent lymphoma. Cancer 100(6):1186-9, 3/2004. PMID: 15022285.
85. Tsimberidou AM, Giles F, Romaguera J, Duvic M, Kurzrock R. Activity of interferon-alpha and isotretinoin in patients with advanced, refractory lymphoid malignancies. Cancer 100(3):574-80, 2/2004. PMID: 14745875.
86. Younes A, Romaguera J, Hagemeister F, McLaughlin P, Rodriguez MA, Fiumara P, Goy A, Jeha S, Manning JT, Jr, Jones D, Abruzzo LV, Medeiros LJ. A pilot study of rituximab in patients with recurrent, classic Hodgkin disease. Cancer 98(2):310-4, 7/2003. PMID: 12872350.
87. Romaguera JE, Medeiros LJ, Hagemeister FB, Fayad LE, Rodriguez MA, Pro B, Younes A, McLaughlin P, Goy A, Sarris AH, Dang NH, Samaniego F, Brown HM, Gagneja HK, Cabanillas F. Frequency of gastrointestinal involvement and its clinical significance in mantle cell lymphoma. Cancer 97(3):586-91, 2/2003. PMID: 12548600.
88. Wilder RB, Romaguera JE, Tucker SL, Ha CS, Hess MA, Cabanillas F, Cox JD. Results with chemotherapy comprised of cyclophosphamide, doxorubicin, vincristine, and prednisone followed by radiotherapy with or without prechemotherapy surgical debulking for patients with bulky, aggressive lymphoma. Cancer 94(3):601-5, 2/2002. PMID: 11857290.
89. Batty N, Ghonimi E, Feng L, Fayad LE, Younes A, Rodriguez MA, Romaguera JE, McLaughlin P, Samaniego F, Kwak LW, Hagemeister FB. Economics Impact on Use of Blood Transfusions and Eryhropoietin-Stimulating Agents in Patients with Diffuse Large B-Cell Lymphoma. Cancer. Submitted.
90. Oki Y, Durand JB, Hagemeister F, Fanale M, Romaguera JE, Pro B, Fowler N, Younes Y, Astrow A, Kwak LW, Samaniego F, McLaughlin P, Wang M, Fayad L, Lenihan DJ, Fisch M, Rodriguez MA. Phase II study of rituximab, cyclophosphamide, vincristine, prednisone, and pegylated liposomal doxorubicin in elderly patients with diffuse large b-cell lymphoma. Submitted.

Invited Articles

1. Romaguera JE, Bycott P, Moran P, Coiffier B, Kang L, Crump M, Hess G, Gisselbrecht C, Offner F. 12TRSL004 Effect of Prognostic Risk Classification on Temsirolimus Efficacy and Safety in Patients with Relapsed or Refractory Mantle Cell Lymphoma. In Press.
2. Romaguera JE. Mantle Cell Lymphoma. Hematologia, Citocinas, Immunoterapia y Terapia Celular. 7/2003.

Editorials

1. Westin JR, Chu F, Zhang M, Fayad LE, Kwak LW, Fowler N, Romaguera J, Hagemeister F, Fanale M, Samaniego F, Feng L, Baladandayuthapani V, Wang Z, Ma W, Gao Y, Wallace M, Vence LM, Radvanyi L, Muzzafar T, Rotem-Yehudar R, Davis RE, Neelapu SS. Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial. Lancet Oncol 15(1):69-77, 1/2014. e-Pub 12/11/2013. PMID: 24332512.

Abstracts

1. Romaguera JE, Fowler N, Fanale MA, Shah JJ, McLaughlin P, Pro B, Selvaraj V, Braun FK, Mathur R, Feng L, Neelapu SS, Kwak LW. A Single Center Phase II Trial Of 90yttrium-Ibritumomab-Tiuxetan Produces High Response Rates As First-Line Therapy For Early Stage B Cell Indolent Lymphoma, Including Bulky Disease. Blood (ASH Annual Meeting Abstracts) 122(21):3039, 12/2013.
2. Noorani M, Davis RE, Neelapu SS, Rodriguez A, Hagemeister FB, Fowler N, Wang M, Fanale MA, Samaniego F, Dabaja BS, Pinnix C, Kwak LW, Romaguera JE, Khouri I, Westin JR, Fayad LE. Double Hit Lymphoma: M.D. Anderson Experience. Blood (ASH Annual Meeting Abstracts) 122(21):1776, 12/2013.
3. Kantarjian HM, Cortes JE, Jabbour EJ, Faderl SH, Wierda WG, Garcia-Manero G, Ferrajoli A, Verstovsek S, Burger JA, Fayad LE, Romaguera JE, Garris R, Ravandi R, O'Brien S, Thomas D. Long Term Follow-Up Of De Novo Or Minimally Treated Burkitt Lymphoma/Leukemia (BL/B-ALL) After Frontline Therapy Per The Hyper-CVAD Regimen With Or Without Rituximab: 20-Year Cumulative Experience. Blood (ASH Annual Meeting Abstracts) 122(21):3917, 12/2013.
4. Rodriguez MA, Deitcher SR, Younes A, Fayad LE, Goy A, Dang NH, Forman A, McLaughlin P, Pro B, Romaguera JE, Samaniego F, Silverman JA, Sarris AH, Cabanillas F. Long Term Results Of a Phase 2 Study Of Vincristine Sulfate Liposome Injection (Marqibo®) Substituted For Non-Liposomal Vincristine In CHOP With Or Without Rituximab For Patients With Untreated Aggressive Non-Hodgkin’s Lymphomas. Blood (ASH Annual Meeting Abstracts) 122(21):3033, 12/2013.
5. Romaguera JE, Kwak LW, Hagemeister FB, Rodriguez MA, Oki Y, Westin JR, Turturro F, Overman MJ, Neelapu SS, Fowler N, Fayad LE. Long-Term Remissions Of Patients With Follicular Lymphoma Grade 3 Treated With Rituximab, Cyclophospamide, Doxorubicine, Vincristine and Prednisone (R-CHOP). Blood (ASH Annual Meeting Abstracts) 122(21):3028, 12/2013.
6. Saliba RM, Ledesma C, Chancoco CM, Alexander T, Alousi A, Hosing CM, Khouri I, Nieto Y, Popat U, Shpall EJ, Fanale MA, Oki Y, Romaguera JE, Neelapu SS, Younes A, Champlin RE. Reduced-Intensity Conditioning (RIC) and Allogeneic Stem Cell Transplantation (allo-SCT) For Relapsed/Refractory Hodgkin Lymphoma (HL) In The Brentuximab Vedotin Era: Favorable Overall and Progression-Free Survival (OS/PFS) With Low Transplant-Related Mortality (TRM). Blood (ASH Annual Meeting Abstracts) 122(21):410, 12/2013.
7. Thall PF, Valdez BC, Hosing CM, Ahmed S, Jones RB, Shah N, Anderlini P, Qazilbash MH, Popat UR, Bashir Q, Shpall EJ, Alousi A, Kebriaei P, Fox P, Bassett R, Chancoco C, Oki Y, Fanale MQ, Fowler N, Hagemeister FB, Romaguera JE, Champlin RE, Andersson BS. Vorinostat (SAHA) Combined With High-Dose Gemcitabine/Busulfan/Melphalan (SAHA/Gem/Bu/Mel) With Autologous Stem-Cell Transplant (ASCT) In Patients With Refractory Lymphomas. Blood (ASH Annual Meeting Abstracts) 122(21):2095, 12/2013.
8. Westin J, Chu F, Fayad LE, Kwak LW, Fowler N, Romaguera JE, Hagemeister F, Fanale M, Samaniego F, Feng F, Baladadayuthapani V, Rotem-Yehudar R, Davis R, Neelapu S. Phase II safety and efficac study of pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma. Hematol Oncol 31(1):96-150, 6/2013.
9. Wang M, Rule S, Martin P, Auer R, Kahl BS, Jurczak W, Advani RH, Romaguera J, Williams ME, Barrientos JC, Chmielowska E, Radford JA, Stilgenbauer S, Dreyling M, Jedrzejczak WW, Johnson P, Spurgeon Se, Li L, Zhang L, Newberry KJ, Ou Z, Cheng N, Fang B, McGreivy J, Clow F, Buggy J, Chang BY, Beaupre DM, Kunkel LA, Goy A, Blum KA. Updated interim results of an international, multicenter, phase 2 study of ibrutinib (PCI-3276) in relapsed or refractory (R/R) mantle cell lymphoma (MCL). 12th International Conference on Malignant Lymphoma (ICML), 6/2013.
10. Wang M, Rule SA, Martin P, Goy A, Auer R, Kahl BS, Jurczak W, Advani RH, Romaguera JE, McGreivy J, Clow F, Stevens-Brogan M, Kunkel L, Blum KA. Interim Results of an International, Multicenter, Phase 2 Study of Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765), in Relapsed or Refractory Mantle Cell Lymphoma (MCL): Durable Efficacy and Tolerability with Longer Follow-up. Blood Blood (ASH Annual Meeting Abstracts)(120):904, 11/2012.
11. Fowler NH, Neelapu SS, Hagemeister FB, McLaughlin P, Kwak LW, Romaguera JE, Fanale MA, Fayad LE, Orlowski RZ, Wang M, Turturro F, Oki Y, Lacerte LC, Samaniego F. Lenalidomide and Rituximab for Untreated Indolent Lymphoma: Final Results of a Phase II Study. Blood Blood (ASH Annual Meeting Abstracts)(120):901, 11/2012.
12. Westin JR, Chu F, Fayad LE, Kwak LW, Fowler NH, Romaguera JE, Hagemeister FB, Fanale M, Samaniego F, Allen R, Feng L, Baladandayuthapani V, Rotem-Yehudar R, Neelapu S. Phase II Safety and Efficacy Study of CT-011, a Humanized Anti-PD-1 Monoclonal Antibody, in Combination with Rituximab in Patients with Relapsed Follicular Lymphoma. Blood Blood (ASH Annual Meeting Abstracts)(120):793, 11/2012.
13. Fanale MA, Lai CM, Rimes SA, Ramirez MM, Hagemeister FB, Fowler NH, Younes A, Fayad LE, Rodriguez MA, Turturro F, Samaniego F, Romaguera JE, Levin VA, Horowitz SB, Woolery JB, Milbourne A. Positive Maternal-Fetal Outcomes with Treatment of Lymphoma During Pregnancy: UT MD Anderson Cancer Center Prospective Experience. Blood Blood (ASH Annual Meeting Abstracts)(120):3670, 11/2012.
14. Oki Y, Westin JR, Fowler N, Neelapu S, Hagemeister FB, McLaughlin P, Kwak LW, Romaguera JE, Fanale M, Younes A, Rodriguez MA, Orlowski RZ, Wang M, Ouzounian S, Samaniego F, Fayad LE. R-HCVAD Alternating with R-Methotrexate Cytarabine in Younger Patients (pts) with IH and High-Risk Age Adjusted-IPI DLBCL. Blood Blood (ASH Annual Meeting Abstracts)(120):3707, 11/2012.
15. Samaniego F, Wise J, Tao R, Zhu F, Ao X, Chen Z, Zhuang W, Braun FK, Mathur R, Romaguera JE, Fayad LE, Wang M, McLaughlin P, McDonnell TJ, Patel KP, Neelapu SS, Kwak LW, Berkova Z. Regulation of Fas-mediated Apoptosis in B-Cell Lymphomas by Nucleolin. Blood Blood (ASH Annual Meeting Abstracts)(120):2406, 11/2012.
16. Oki Y, Chuang H, Chasen B, Pan , Fanale MA, Dabaja BS, Fowler NH, Romaguera JE, Fayad LE, Hagemeister FH, Rodriguez MA, Neelapu SS, Samaniego F, Kwak LW, Younes A. The Prognostic Value of Interim PET Scan in Patients with Classical Hodgkin Lymphoma. Blood Blood (ASH Annual Meeting Abstracts)(120):1529, 11/2012.
17. Batty N, Ghonimi E, Feng L, Fayad L, Younes A, Rodriguez AM, Romaguera JE, McLaughlin P, Samaniego F, Kwak LW, Hagemeister FB. Comparison of the international prognostic factors index (IPI) with the absolute monocyte and lymphocyte prognostic index (AMLPI) for patients (Pts) with diffuse large b-cell lymphoma (DLBCL) receiving R-CHOP. J Clin Oncol J Clin Oncol(30):8067, 2012, 6/2012.
18. Wang M, Fowler N, Wagner-Bartak N, Hagemeister F, Neelapu S, Fanale M, Younes A, Zhang L, Sun L, Badillo M, Bejarano M, Champlin R, Kwak L, Feng L, Byrne C, Bell N, Zeldis J, Romaguera J, Fayad L. Oral lenalidomide plus 4 doses of rituximab induced prolonged remission in a cohort of patients with DLBCL and grade 3 follicular lymphoma: a completed phase II clinical trial. 16th Congress of the European Hematology Association (EHA) (#237), 2012.
19. Jung HJ, Chen Z, Wang M, Fayad LE, Romaguera JE, Kwak LW, McCarty N. Calcium blockers decrease the bortezomib resistance in mantle cell lymphoma via manipulation of tissue transglutaminase activities. Blood Blood (ASH Meeting Abstract)(119):2568-2578, 11/2011.
20. Vadhan-Raj S, Spasojevic I, Zhou S, Romaguera JE, Fanale M, Fayad LE, Fowler NH, Huen A, Hagemeister FB, Rodriguez MA, Neelapu SS, Samaniego F, Younes A, Kwak LW. Effects of Aprepitant on Drug Metabolism in Lymphoma Patients Receiving Multi-Day Chemotherapy Regimen of Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, + Rituxan (R/CHOP): Randomized, Cross-Over Study. Blood Blood (ASH Annual Meeting Abstracts)(118):1613, 11/2011.
21. Oki Y, Copeland A, Hagemeister F, Fayad LE, Fanale M, Romaguera JE, Younes A. Experience with obatoclax mesylate (GX15-070), a small molecule pan–Bcl-2 family antagonist in patients with relapsed or refractory classical Hodgkin lymphoma. Blood Blood (ASH Meeting Abstracts)(119):2171-2172, 11/2011.
22. Jones RJ, Baladandayuthapani V, Neelapu S, Fayad LE, Romaguera JE, Wang M, Sharma R, Yang D, Orlowski RZ. HDM-2 inhibition suppresses expression of ribonucleotide reductase subunit M2, and synergistically enhances gemcitabine-induced cytotoxicity in mantle cell lymphoma. Blood Blood (ASH Meeting Abstract)(118):4140-4149, 11/2011.
23. Thomas DA, Kantarjian HM, Faderl S, Wierda WG, Jabbour E, Garcia-Manero G, Ferrajoli A, Verstovsek S, Burger JA, Fayad LE, Romaguera JE, Garris R, Cortes JE, O'Brien S. Hyper-CVAD and Rituximab for De Novo Burkitt Lymphoma/Leukemia. Blood Blood (ASH Annual Meeting Abstracts)(118):2698, 11/2011.
24. Younes A, Oki Y, McLaughlin P, Copeland A, Goy A, Pro B, Feng L, Yuan Y, Chuang H, Macapinlac H, Hagemesiter F, Romaguera J, Samaniego F, Fanale M, Dabaja B, Rodriguez MA, Dang N, Kwak L, Neelapu S, Fayad L. Phase II study of rituximab plus ABVD in patients with newly diagnosed classical hodgkin lymphoma. Blood Blood (ASH Meeting Abstract)(119):4123-4128, 11/2011.
25. Younes A, Copeland A, Fanale M, Fayad LE, Romaguera JE, Kwak LW, Neelapu SS, Hagemeister F, Pro B, de Castro Faria S, Ji Y, Berry D, Buglio D, Medeiros J. Safety and efficacy of the novel combination of panobinostat (LBH589) and everolimus (RAD001) in relapsed/refractory hodgkin and non-hodgkin lymphoma. Blood Blood (ASH Annual Meeting Abstracts)(118):3718, 11/2011.
26. Thompson MA, Wei C, Moyer AM, Cunningham JM, Wang L, Fayad LE, Feng L, Rodriguez MA, Cabanillas F, Kantarjian HM, Kwak LW, Romaguera JE. Single Nucleotide Polymorphisms (SNPs) in Genes for Glutathione-Related Metabolism, Cyclin D1, and DNA Repair As Predictive Biomarkers in Mantle Cell Lymphoma Patients Treated with R-HyperCVAD with Ten Year Clinical Follow-up. Blood Blood (ASH Annual Meeting Abstracts)(118):3650 (#3650), 11/2011.
27. Samaniego F, Hagemeister F, Mclaughlin P, Kwak LW, Romaguera JE, Fanale MA, Neelapu SS, Fayad LE, Orlowski RZ, Wang M, Lacerte L, Fowler NH. High response rates with lenalidomide plus rituximab for untreated indolent B-cell non-Hodgkin lymphoma, including those meeting GELF criteria. J Clin Oncol J Clin Oncol (2011 ASCO Meeting)(29):8030, 6/2011.
28. Fanale MA, Vigil K, Lai C, Feng L, Dong W, Younes A, Romaguera JE, Fayad LE, Hagemeister FB, Mulanovich V. Outcomes of HIV-positive lymphoma patients treated in the highly active antiretroviral therapy (HAART) era. J Clin Oncol J Clin Oncol 29(18528), 6/2011.
29. Romaguera J, Wang M, Hagemeister F, Weaver P, Hartig K, Fanale M, Fayad LE, Fowler N, Orlowski R, Feldman T, Wagner-Bartak N, Smith J, Ford P, Kwak L, Goy A. Phase I-II study of bortezomib in combination with R-HCVAD and R-Methotrexate/ cytarabine (R-MA) in untreated mantle cell lymphoma (MCL). 11th International Conference on Malignant Lymphoma, Lugano, Switzerland, 6/2011.
30. Romaguera J, Wang M, Hagemeister F, Weaver P, Hartig K, Fanale M, Fayad L, Fowler N, Orlowski R, Feldman T, Wagner-Bartak N, Smith J, Ford P, Kwak L, Goy A. Phase I-II study of bortezomib in combination with R-HCVAD and R-Methotrexate/ cytarabine (R-MA) in untreated mantle cell lymphoma (MCL). 16th European Hematolgy Conference, London, England 22(10):1093, 6/2011.
31. Rodriguez MA, Durand J, Astrow AB, Bury MJ, Fanale MA, Hagemeister FB, Huang X, McLaughlin P, Neelapu SS, Pro B, Kwak LW, Fayad L, Romaguera JE, Younes A, Fisch M. Phase II study of RCHOP with pegylated liposomal doxorubicin (DRCOP) for patients older than age 60 with untreated diffuse large B-cell lymphoma (DLBCL). J Clin Oncol J Clin Oncol 29(8053), 6/2011.
32. Wang M, Garcia K, Zhou Y, You B, Guo Y, Forman A, Chiang J, Orlowski R, Shah J, Alexanian R, Thomas S, Qazilbash M, Badillo M, Chen Y, Delasalle K, Green V, Romaguera J, Cohen L. Electroacupuncture is an effective therapeutic modality for bortezomib-or thalidomide-induced peripheral neuropathy in patients with multiple myeloma: A Pilot study. 13th International Myeloma Workshop (IMW) (#P-367), 2011.
33. Wang M, Fayad L, Wagner-Bartak N, Hagemeister F, Neelapu S, Finale M, Younes A, Cabanillas F, Zhang L, Champlin R, Kwak L, Feng L, Bell N, Zeldis J, Romaguera J. Oral lenalidomide plus 4 doses of rituximab induced prolonged remissions in relapsed/refractory mantle cell lymphoma: a completed phase I/II clinical trial. 11th International Conference on Malignant Lymphoma (ICML), Lugano, 2011.
34. Thomas DA, Faderl S, O'Brien S, Wierda W, Garcia-Manero G, Verstovsek S, Konopleva M, Kadia T, Kornblau S, Fayad L, Romaguera JE, Cortes JE, Kantarjian H. Long-Term Outcome for De Novo Lymphoblastic Lymphoma (LL) After Frontline Therapy with Hyper-CVAD Regimen and Variants. Blood (ASH Annual Meeting Abstracts) 116(21):2831, 11/2010.
35. Thomas DA, O'Brien S, Cortes JE, Faderl S, Wierda WG, Garcia-Manero G, Jabbour E, Ferrajoli A, Verstovsek S, Burger JA, Garris R, Romaguera JE, Hagemeister FB, Kantarjian H. Long-Term Outcome for De Novo or Minimally Treated Burkitt-Type Lymphoma/Leukemia (BL/B-ALL) After Therapy with Hyper-CVAD and Rituximab. Blood (ASH Annual Meeting Abstracts) 116(21):1781, 11/2010.
36. Fanale MA, Lai CM, McLaughlin P, Romaguera JE, Fayad LE, Hagemeister FB, Samaniego F, Rodriguez MA, Neelapu SS, Shah JJ, Kwak LW, Dong W, Reed V, Dabaja BS, Popat U, Younes A. Outcomes of Nodular Lymphocyte Predominant Hodgkin's Lymphoma (NLPHL) Patients Treated with R-CHOP. Blood (ASH Annual Meeting Abstracts) 116(21):2812, 11/2010.
37. Vadhan-Raj S, Hagemeister FB, Fayad LE, Zhou X, ORoark SS, Ames K, Rodriguez MA, Fanale MA, Pro B, Johnson MM, McLaughlin P, Bueso-Ramos CE, Younes A, Kwak LW, Romaguera JE. Randomized, Double-Blind, Placebo-Controlled, Dose and Schedule-Finding Study of AMG 531 In Chemotherapy-Induced Thrombocytopenia (CIT): Results of a Phase I/II Study. Blood 116(21):1544, 11/2010.
38. Batty N, Hagemeister FB, Romaguera JE, Rodriguez MA, McLaughlin P, Samaniego F, Copeland A, Dabaja BS, Younes A. ABVD chemotherapy with interferon for advanced-stage classical Hodgkin's lymphoma: A 10-year follow-up study. J Clin Oncol 28(15s):8057, 6/2010.
39. Pro B, Perini GF, Feng L, Romaguera JE, Rodriguez MA, McLaughlin P, Hagemeister FB, Fayad LE, Kadia TM. Clinical features and treatment outcomes of angioimmunoblastic T-cell lymphoma. J Clin Oncol 28(15s):8048, 6/2010.
40. Perini GF, Romaguera JE, Rodriguez MA, Pro B, Younes A, Fowler N, Hagemeister F, Samaniego F, Kwak L, Fayad LE. Diffuse large B-cell lymphoma (DLBCL) with bone marrow (BM) involvement. clinical presentation, central nervous system (CNS) relapses, and outcomes of 121 patients treated at M. D. Anderson Cancer Center. J Clin Oncol 28(15s):8072, 6/2010.
41. Pozadzides JV, Perini G, Hess M, Romaguera JE, Hagemeister F, McLaughlin P, Fayad LE, Khouri IF, Hosing C, Pro B. Prognosis and treatment of patients with peripheral T-cell lymphoma: The M. D. Anderson Cancer Center experience. J Clin Oncol 28(15s):8051, 6/2010.
42. Manoukian GE, Hagemeister FB, McLaughlin P, Fayad L, Samaniego F, Goy A, Romaguera JE, Pro B, Cabanillas F, Rodriguez MA. Rituximab, fludarabine, mitoxantrone, and dexamethasone (R-FND) for patients with relapsed indolent B-cell lymphoma (RIL). J Clin Oncol 28(15s):8078, 6/2010.
43. Wang M, Fayad LE, Hagemeister FB, Neelapu S, Samaniego F, McLaughlin P, Samuels B, Yi Q, Pro B, Fanale M, Shah J, Younes A, Bell N, Knight R, Zeldis JB, Cabanillas F, Kwak L, Romaguera JE. A Phase I/II Study of Lenalidomide in Combination with Rituximab in Relapsed/Refractory Mantle Cell Lymphoma. Blood (ASH Annual Meeting Abstracts) 114:2719, 11/2009.
44. Younes A, Copeland AR, Romaguera JE, Fayad LE, Fanale M, de Castro Faria S, Medeiros LJ, Percy Ivy S. Clinical and Biologic Activity of the Heat Shock Protein-90 (HSP-90) Inhibitor 17-AAG in Patients with Relapsed Lymphoma. Blood (ASH Annual Meeting Abstracts) 114:3744, 11/2009.
45. Copeland AR, Cao Y, Fanale M, Fayad L, McLaughlin P, Pro B, Hagemeister F, Romaguera JE, Samaniego F, Rodriguez MA, Younes A. Final Report of a Phase-II Study of Rituximab Plus ABVD for Patients with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma. Results of Long Follow up and Comparison to Institutional Historical Data. Blood (ASH Annual Meeting Abstracts) 114:1680, 11/2009.
46. Younes A, Gordon L, Kim S, Romaguera JE, Copeland AR, Castro Farial S, Kwak L, Fayad LE, Hagemeister F, Fanale M, Lambert J, Bagulho T, Morariu-Zamfir R. Phase I Multi-Dose Escalation Study of the Anti-CD19 Maytansinoid Immunoconjugate SAR3419 Administered by Intravenous (IV) Infusion Every 3 Weeks to Patients with Relapsed/ Refractory B-Cell Non-Hodgkin's Lymphoma (NHL). Blood (ASH Annual Meeting Abstracts) 114:585, 11/2009.
47. Vadhan-Raj S, Fayad L, Fanale M, Pro B, Rodriguez MA, Hagemeister F, Ames K, Bueso-Ramos CE, Zhou X, McLaughlin P, Fowler N, Shah J, Samaniego F, Younes A, Kwak L, Romaguera JE. Randomized Clinical Trial of Rasburicase Administered as a Standard Fixed Five Days Dosing Vs a Single Dose Followed by as Needed Dosing in Adult Patients with Hematologic Malignancies at Risk for Developing Tumor Lysis Syndrome. Blood (ASH Annual Meeting Abstracts) 114:105, 11/2009.
48. Younes A, Kirschbaum M, Sokol L, Yee L, Romaguera JE, Goyal L, Hsu C, Hwang Y, Gorski K, Wong S, Beaupre D. Safety and Tolerability of Conatumumab in Combination with Bortezomib or Vorinostat in Patients with Relapsed or Refractory Lymphoma. Blood (ASH Annual Meeting Abstracts) 114:1708, 11/2009.
49. Samaniego F, Fanale M, Pro B, Hagemeister FB, McLaughlin P, Romaguera JE, Neelapu S, Rodriguez A, Fayad L, Younes A, Kwak L. Pentostatin, cyclophosphamide, and rituximab (PCR) achieve high response rates in indolent B-cell lymphoma without prolonged myelosuppression. Blood 112:835, 11/2008.
50. Romaguera JE, Fayad L, McLaughlin P, Pro B, Rodriguez MA, Wang M, Weaver P, Hartig K, Kwak L, Feldman T, Smith J, Ford P, Goldberg S, Pecora A, Goy A. Phase I trial of bortezomib in combination with rituximab-hyperCVAD/methotrexate and cytarabine for untreated mantle cell lymphoma. Blood 112:3051, 11/2008.
51. Romaguera J, Fayad L, Rodriguez A, Hagemeister FB, Pro B, McLaughlin P, Younes A, Samaniego F, Shah J, Weaver P, Hartig K, Cabanillas F, Kwak L, Kantarjian H, Wang M. Rituximab (R) + hypercvad alternating with R-Methotrexate/Cytarabine after 9 years: Continued high rate of failure-free survival in untreated mantle cell lymphoma (MCL). Blood 112:833, 11/2008.
52. Romaguera JE, Coiffier B, Crump M, Herbrecht R, Verhoef G, Hanushevsky O, Strahs A, Hewes B, Berkenblit A, Hess G. Supportive Efficacy Analyses for the Phase 3 Study of Temsirolimus Versus Investigator’s Choice Therapy for the Treatment of Patients with Relapsed or Refractory Mantle Cell Lymphoma. Blood (ASH Annual Meeting Abstracts) 112:1559, 11/2008.
53. Romaguera JE. Mantle Cell Lymphoma: Frontline and Salvage Therapy. Current Hematologic Malignancy Reports 3(4):204-209, 10/2008.
54. Suh GK, McLaughlin P, Romaguera JE, Hagemeister FB, Pro B, Khouri IF, Samaniego F, Rodriguez MA, Fayad LE, Feng L, Younes A. Long-term follow-up of paclitaxel plus rituximab (TTR) for patients with relapsed and refractory B-cell non-Hodgkin's lymphoma. JCO 26(15S):478s (#8599), 5/2008.
55. Romaguera JE, Wang M. Lenalidomide in combination with rituximab demonstrated early evidence of efficacy in a phase I/II study in relapsed/refractory Mantle Cell Lymphoma, 2008 Mantle Cell Lymphoma Workshop, Dallas, Texas, 3/2008.
56. Samaniego F, Pro B, Nunez R, McLaughlin P, Fanale M, Kwak L, Romaguera J. High response rates for stage I-II indolent B-cell lymphoma with yttrium-90 ibritumomab tiuxetan (zevalin). Annals of Oncology 19(4):iv208 (#422), 2008.
57. Wang M, Zhang L, Fayad L, Hagemeister FB, Neelapu S, Samaniego F, Pro B, Younes A, Miller S, Knight RD, Zeldis JB, Yi Q, Romaguera JE. Lenalidomide and rituximab are a promising combination in vitro, in vivo preclinically and in a phase I/II clinical trial in relapsed/refractory mantle cell lymphoma. Blood 112:3058, 2008.
58. Wang M, Fayad L, Hagemeister F, Neelapu S, Samuels B, Samaniego F, Pro B, Yi Q, Bell N, Byrne C, Weaver P, Hartig K, Knight R, Zeldis J, Kwak L, Romaguera J. Lenalidomide in combination with rituximab is effective with manageable toxicity in a phase I/II study in relapsed/refractory mantle cell lymphoma. Annals of Oncology 19(4):iv174 (#306), 2008.
59. Romaguera JE, Flynn PJ, Hasler GR. Methotrexate/Cytarabine only as initial management of untreated mantle cell lymphoma: results of a phase II CCOP trial. Annals of Oncology 19(4):iv213 (#443), 2008.
60. Samaniego F, Fanale M, Hagemeister F, McLaughlin P, Romaguera J, Neelapu S, Rodriguez A, Fayad L, Younes A, Kwak L. Pentostatin combined with cyclophosphamide, and rituximab (PCR) achieve high response rates in indolent B-cell lymphoma. Annals of Oncology 19(4):iv182 (#334), 2008.
61. Romaguera JE, Pro B, Fayad L, McLaughlin P, Wang M, Weaver P, Hartig K, Hagemeister F, Rodriguez MA, Younes A, Samaniego F, Fanale M, Kwak L, Feldman T, Goy A. Phase I trial of bortezomib in combination with rituximab-hypercvad/methotrexate and cytarabine for untreated mantle cell lymphoma. Annals of Oncology 19(4):iv214 (#444), 2008.
62. Wedgwood A, Fanale M, Fayad L, McLaughlin P, Hagemeister F, Pro B, Romaguera J, Rodriguez MA, Samaniego F, Younes A. Rituximab + ABVD improves event-free survival (EFS) in patients with classical hodgkin lymphoma in all international prognostic score (IPS) groups and in patients who have PET positive disease after 2-3 cycles of therapy. Blood 110 (#215), 2008.
63. Wang M, Shi Y, Zhang L, Han X, Yang J, Qian J, Hong S, Lin P, Romaguera J, Kwak LW, Yi Q. A SCID-hu In Vivo Mouse Model of Human Primary Mantle Cell Lymphoma. Blood 110(11):691a, 11/2007.
64. Zhang L, Shi Y, Han X, Yang J, Qian J, Kwak L, Romaguera JE, Yi Q, Wang M. Bortezomib Is Synergistic with Rituximab and Cyclophosphamide in Inducing Apoptosis of Mantle Cell Lymphoma Cells In Vitro and In Vivo. Blood 110(11):200B, 11/2007.
65. Thompson MA, Kadia TM, Nebiyou Bekele B, Wang M, Romaguera JE. Cyclin D1 Polymorphisms as Predictive and Prognostic Molecular Markers in 90 Mantle Cell Lymphoma Patients Treated with R-HyperCVAD. Blood 110(11):472a, 11/2007.
66. Wang M, Fayad L, Hagemeister F, Neelapu S, Samuels B, Samanigo F, Pro B, Yi Q, Bell N, Byrne C, Weaver P, Hartig K, Knight R, Zeldis J, Kwak L, Romaguera J. Lenalidomide (Len) in Combination with Rituximab (R) Demonstrated Early Evidence of Efficacy in a Phase I/II Study in Relapsed/Refractory Mantle Cell Lymphoma (MCL). Blood 110(11):755a, 11/2007.
67. Rodriguez MA, Fanale M, Hagemeister F, McLaughlin P, Pro B, Romaguera JE, Kwak L, Fayad L, Huang X, Durand JB. Phase II Study of RCHOP with Pegylated Liposomal Doxorubicin (DRCOP) for Patients > 60 Years Old with Untreated Diffuse Large B Cell Lymphoma (DLBCL). Blood (ASH Annual Meeting Abstracts) 110:4468, 11/2007.
68. Pro B, Fayad LE, Romaguera JE, Fanale M, Younes A, Hagemeister F, Samaniego F, McLaughlin P, Rodriguez MA, Kwak L, Dang N. Preliminary Results of a Phase II Study of HCVIDDoxil Alternated with Methotrexate-Cytarabine in Patients with Newly Diagnosed T-Cell Lymphoma. Blood 110(11):1013A, 11/2007.
69. Fayad LE, Pro B, Hagemeister F, Cabanillas F, Samaniego F, McLaughlin P, Wang M, Neelapu S, Kwak L, Romaguera JE, Rodriguez MA. R-HCVAD/R-MTX-ARAC Is an Effective Regimen for Untreated Diffuse Large B-Cell Lymphoma (DLBCL) with Aggressive Features in Patients Younger Than 60 Years. Blood 110(11):387a, 11/2007.
70. Wedgwood AR, Fanale M, Fayad LE, McLaughlin P, Hagemeister FB, Pro B, Romaguera JE, Rodriguez MA, Samaniego F, Younes A. Rituximab + ABVD Improves Event-Free Survival (EFS) in Patients with Classical Hodgkin Lymphoma in All International Prognostic Score (IPS) Groups and in Patients Who Have PET Positive Disease after 2–3 Cycles of Therapy. Blood 110(11):71a, 11/2007.
71. Overman MJ, Feng L, Pro B, McLaughlin P, Hess M, Samaniego F, Younes A, Romaguera JE, Hagemeister FB, Kwak L, Cabanillas F, Rodriguez MA, Fayad LE. The Addition of Rituximab to CHOP Chemotherapy Improves Response Rate, Failure-Free Survival and Overall Survival for Follicular Grade 3 Lymphoma Compared to CHOP Alone. Blood 110(11):388a, 11/2007.
72. Zhou Y, Wang H, Du X, Yi Q, Zhang Y, Romaguera JE, Wang M. Trend and Geographic Variations in the Incidence of Mantle Cell Lymphoma in the United States over 30 Years from 1975 to 2004. Blood 110(11):172B, 11/2007.
73. Wang M, Fayad L, Hagemeister F, Neelapu S, Bell N, Byrne C, Knight R, Zeldis J, Kwak L, Romaguera J. A phase I/II study of lenalidomide (Len) in combination with rituximab (R) in relapsed/refractory mantle cell lymphoma (MCL) with early evidence of efficacy. Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I 25(18S), 6/2007.
74. Wang M, Zhang L, Han X, Yang J, Qian J, Hong S, Samaniego F, Romaguera JE, Yi Q. Atiprimod inhibits the growth of mantle cell lymphoma in vitro and in vivo and induces apoptosis via activating the mitochondrial pathways. Blood 109(12):5455-5462, 6/2007. e-Pub 2/2007. PMID: 17317853.
75. Huen A, Romaguera JE, Fayad LE, Teegala SR, Ji Y, Vadhan-Raj S. Increased toxicity associated with delayed clearance of methothrexate (MTX) in patients with lymphoma receiving high-dose MTX. Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I. 25(18S), 6/2007.
76. Rodriguez MA, Temple S, Fayad LE, Hagemeister F, McLaughlin P, Romaguera JE, Cabanillas F. Predictive value for survival of a risk model of two serological markers, beta-2-microglobulin (B2M) and lactic dehydrogenase (LDH), in diffuse large cell lymphoma (DLCL). Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I. 25(18S), 6/2007.
77. Fayad L, Temple S, Pro B, Hagemeister F, Cabanillas F, Samaiego F, McLaughlin P, Wang M, Kwak L, Romaguera JE, Rodriguez MA. R-HCVAD/R-MTX-ARAC is an effective regimen for untreated diffuse large B-cell lymphoma (DLBCL) with aggressive features: M. D. Anderson experience in 40 patients. Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I. 25(18S), 6/2007.
78. Teegala SR, Zhou X, Huen A, Ji Y, Fayad LE, Romaguera JE, Vadhan-Raj S. Risk factors for neutropenic fever in lymphoma patients receiving chemotherapy. Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I. 25(18S), 6/2007.
79. Zhou X, Teegala SR, Huen A, Ji Y, Fayad LE, Romaguera JE, Hagemeister FB, Vadhan-Raj S. Risk factors for severe anemia requiring red blood cell transfusions in lymphoma patients receiving chemotherapy. Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I. 25(18S), 6/2007.
80. Zhou Y, Wang H, Zhang Y, Du X, Kwak L, Romaguera J, Wang M. Trend and geographic variations in the incidence of mantle cell lymphoma in the United States from 1975 to 2003. Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I. 25(18S), 6/2007.
81. Pro B, Nunez RF, Romaguera J, Rodriguez MA, Hagemeister FB, Fayad L. Achievement of FDG-PET Negativity Does Not Predict Durable Responses in T-Cell Lymphoma. Blood 108 (#2404), 11/2006.
82. Wang M, Zhang L, Han X, Yang J, Qian J, Wang S, Hong S, Zhang X, Zhou Y, Romaguera JE, Yi K. Atiprimod Inhibits Growth of Mantle Cell Lymphoma In Vitro and In Vivo and Induces Apoptosis Via Activation of the Mitochondrial Pathway. Blood 108 (#2514), 11/2006.
83. Romaguera JE, Fayad L, Rodriguez MA, Hagemeister FB, Pro B, McLaughlin P, Younes A, Samaniego F, Goy A, Sarris AH, Dang NH, Wang L, Kantarjian HM, Beasley V, Medeiros LJ, Katz RL, Cabanillas F. Blastoid Mantle Cell Lymphoma (MCL): 5-yr Failure-Free Survival (FFS) Rate of 50%, without Failures after 2.5 Years Following Treatment with Rituximab (R)-HyperCVAD Alternating with R-Methotrexate/Cytarabine (M/A). Blood 108 (#2749), 11/2006.
84. Fayad L, Overman M, Pro B, McLaughlin P, Samaniego F, Younes A, Romaguera JE, Hagemeister FB, Kwak L, Rodriguez MA. Favorable Results of Rituximab in Combination with CHOP in the Front-Line Treatment of Follicular Lymphoma Grade 3. Blood 108 (#2770), 11/2006.
85. Teegala S, Zhou X, Huen A, Ji Y, Fayad L, Romaguera JE, Hagemeister FB, Vadhan-Raj S. High Incidence of Venous Thromboembolism in Patients with Lymphoma Receiving Chemotherapy: Assessment of Risk Factors. Blood 108 (#4103), 11/2006.
86. Huen A, Zhou X, Teegala S, Ji Y, Fayad L, Romaguera JE, Hagemeister FB, Vadhan-Raj S. Incidence and Risk Factors for Severe Thrombocytopenia in Lymphoma Patients Receiving Chemotherapy. Blood 108 (#3994), 11/2006.
87. Fayad L, Liebmann J, Modiano M, Cohen G, Pro B, Romaguera JE, Stromatt S. Results of a Phase I/II Trial of Pixantrone in Combination with Fludarabine, Dexamethasone, and Rituximab in the Treatment of Patients with Relapsed/Refractory Indolent Non-Hodgkin’s Lymphoma (NHL). Blood 108 (#2758), 11/2006.
88. Younes A, Fayad L, Goy A, McLaughlin P, Pro B, Romaguera JE, Hagemeister FB, Rodriguez MA, Samaniego F, Kwak L, Neelapu S, Medeiros LJ, Wedgwood A, Fanale M. Results of Rituximab Plus ABVD in 65 Newly Diagnosed Patients with Classical Hodgkin Lymphoma: Improvement of Event Free Survival (EFS) in All International Prognostic Score (IPS) Groups. Blood 108 (#2714), 11/2006.
89. Younes A, Rodriguez M, Pro B, McLaughlin P, Romaguera JE, Hagemeister F, Wang M. A phase II study of Yttrium 90 (90Y) Ibritumomab tiuxetan (Zevalin) for treatment of patients with relapsed and refractory mantle cell lymphoma (MCL). . Proceedings of the 9th International Conference on Malignant Lymphomas. Lugano, Switzerland Ann Oncol:Suppl 5 (#201), 2005.
90. Dang J, Pro B, Romaguera JE, Fayad L. Gallium Scan after the second and fourth chemotherapy cycle predicts clinical outcomes in aggressive non-Hodgkin’s lymphomas. J Clin Oncol 23:578s (#6576), 2005.
91. Romaguera J, Fayad L, Rodriguez M, Hagemeister F, Pro B, McLaughlin P, Younes A, Samaniego F, Goy A, Sarris A, Dang N, Medeiros L, Katz R, Gagneja H, Samuels B, Cabanillas F. High rates of failure-free survival (FFS) and overall sirvival (OS) in untreated mantle cell lymphoma (MCL) after rituximab plus hyperCVAD (R-HCVAD) alternating with rituximab plus high-dose methotrexate-cytarabine (R-M/A). Proceedings of the 9th International Conference on Malignant Lymphomas. Lugano, Switzerland. Ann Oncol 16:v94 (#197), 2005.
92. Younes A, McLaughlin P, Romaguera J, Hagemeister F, Pro B, Dang N, Samaniego F, Rodriguez M, Fayad L. Paclitaxel plus topotecan plus rituximab (TTR): An effective salvage program for the treatment of patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma (NHL). Proceedings of the 9th International Conference on Malignant Lymphomas. Lugano, Switzerland. Ann Oncol 16:v101 (#220), 2005.
93. Jabbour E, Hosing C, Pro B, Champlin J, Khouri I, Romaguera JE, Fayad LE. Pre-transplant positive PET/Gallium scans predict poor outcome in relapsed/refractory Hodgkin’s lymphoma (HL). . J Clin Oncol 23:562s (#6509), 2005.
94. Fayad L, Romaguera J, Hart S, Younes A, Pro B, Hagemeister F, McLaughlin P, Dang N, Preti A, Sarris A, Gil F. Report of a phase II study of sphingosomal vincristine (SV) in patients with relapsed or refractory Hodgkin’s disease. Proceeding of American Society of Clinical Oncology 23:591s (#6624), 2005.
95. Younes A, McLaughlin P, Fayad L, Goy A, Medeiros L, Pro B, Romaguera J, Rodriguez M, Samaniego F, Dang N. Rituximab plus ABVD therapy for newly diagnosed patients with classical Hodgkin lymphoma: A novel combination program targeting the cancer cells and the reactive B-cells in the microenvironment. Proceedings of the 9th International Conference on Malignant Lymphomas. Lugano, Switzerland. Ann Oncol 16:v196 (#545), 2005.
96. McLaughlin P, Liu N, Poindexter N, Grimm E, Fayad L, Hagemeister F, Nunez R, Romaguera J, Goy A, Samaniego F, Wang M, Ayala A, Lee B, Reuben J, Kwak L, Rodriguez M. Rituximab plus GM-CSF (Leukine) for indolent lymphoma. Proceedings of the 9th International Conference on Malignant Lymphomas. Lugano, Switzerland (oral). Ann Oncol 16:v68 (#104), 2005.
97. McLaughlin P, Rodriguez M, Hagemeister F, Romaguera J, Sarris A, Younes A, Dang N, Goy A, Samaniego F, Hess M, Lee M, Medeiros L, Fayad L, Pro B, Jiang Y, Ayala A, Cabanillas F. Stage IV indolent lymphoma: A randomized trial of concurrent vs sequential FND (Fludarabine, Mitoxantrone, Dexamethasone) and rituximab with interferon maintenance. Proceedings of the 9th International Conference on Malignant Lymphomas. Lugano, Switzerland. Ann Oncol 16:100 (#247), 2005.
98. Oki Y, Pro B, Delpassand E, Ballaster V, McLaughlin P, Romaguera JE, Wang M, Hagemeister FB, Younes A. A Phase II Study of Yttrium 90 (90Y) Ibritumomab Tiuxetan (Zevalin®) for Treatment of Patients with Relapsed and Refractory Mantle Cell Lymphoma (MCL). . Blood 104:720a (#2632), 11/2004.
99. Dang N, Pro B, Hagemeister FB, Jones D, Samuels B, Rodriguez MA, Goy A, Romaguera JE, Walker P, Kwak L, Fayad L. Interim Analysis of a Phase II Study of Denileukin Diftitox (Ontak) for Relapsed/Refractory T-Cell Non-Hodgkin’s Lymphoma. Blood 104:722a (#2641), 11/2004.
100. Younes A, Fayad L, Romaguera JE, Pro B, Goy A, Dang N, Wang M. Long-Term Safety and Efficacy of Single Administration of a Fixed Dose Pegfilgrastin (Neulasta) in Inducing Neutrophil Count Recovery after ABVD Chemotherapy in Patients with Hodgkin Lymphoma. . Blood 104:245b (#4646), 11/2004.
101. McLaughlin P, Estey E, Glassman A, Romaguera JE, Samaniego F, Ayala A, Hayes K, Maddox A, Preti H, Hagemeister FB. Myelodysplasia and Acute Myeloid Leukemia Folllowing Therapy for Indolent Lymphoma with Fludarabine, Mitoxantrone, Dexamethasone (FND) Plus Rituximab and Interferon Alfa. Blood 104:391a-392a (#1394), 11/2004.
102. Fayad L, Liebmann J, Modiano M, Cohen G, Pro B, Romaguera JE, Davite C, Lymboura M, Comis S, Laffranchi B. Preliminary Results of Phase I/II Trial of BBR-2778 (Pixantrone) in Combination with Fludarabine, Dexamethasone, and Rituximab (FPD-R) in the Treatment of Patients with Relapsed/Refractory Indolent Non-Hodgkin’s Lymphoma (NHL). Blood 104:373a (#1324), 11/2004.
103. Younes A, Pro B, Romaguera JE, Dang N. Safety and Efficacy of Bortezomib (Velcade) for the Treatment of Relapsed Classical Hodgkin’s Disease. Blood 104:722a (#2638), 11/2004.
104. Rodriguez M, Sarris A, Dang N, Fayad L, Goy A, Hagemeister FB, McLaughlin P, Pro B, Romaguera JE, Samaniego F, Younes A, Cabanillas F. Sphingosomal Vincristine in CHOP +/- Rituximab Is a Promising New Treatment for Patients with High Risk Untreated Aggressive Non-Hodgkin’s Lymphoma (NHL): Follow-Up Results of a Phase II Study. Blood 104:234b (#4602), 11/2004.
105. Sarma A, Rodriguez MA, Cabanillas F, Dang NH, McLaughlin P, Hagemeister FB, Pro B, Romaguera JE, Younes A, Grimm EA. A randomized trial of CHOP chemotherapy with or without melatonin in patients with favorable prognosis large B-cell lymphoma. American Society of Clinical Oncology 22:745s, 2004.
106. Sarma A, Rodriguez MA, Cabanillas F, Dang NH, McLaughlin P, Hagemeister FB, Pro B, Romaguera J, Younes A, Grimm EA. A Randomized trial of CHOP chemotherapy with or without melatonin In patients with favorable prognosis large B-cell lymphoma. J Clin Oncol 22(14S):745s, 2004.
107. Romaguera JE, Fayad L, Rodriguez MA, Hagemeister FB, Pro B, McLaughlin P, Younes A, Samaniego F, Goy A, Sarris A, Dang N, Medeiros L, Katz R, Gagneja H, Samuels B, Cabanillas F. Rituximab Plus Hypercvad (R-HCVAD) Alternating with Rituximab Plus High-Dose Methotrexate-Cytarabine (R-M/A) in Untreated Mantle Cell Lymphoma (MCL): Prolonged Follow-Up Confirms High Rates of Failure-Free Survival (FFS) and Overall Survival (OS). Blood 104:40a (#128), 2004.
108. Rodriguez MA, Dang NH, Fayad LE, Goy A, Hagemeister FB, McLaughlin P, Pro B, Romaguera JE, Youens A, Cabanillas F. Sphingosomal vincristine in CHOP in a promising new treatment for elderly, as well as poor prognosis patients with aggressive non-Hodgkin’s lymphoma. . American Society of Clinical Oncology (ASCO) 22:748s, 2004.
109. Rodriguez MA, Dang NH, Fayad L, Goy A, Hagemeister FB, McLaughlin P, Pro B, Romaguera J, Younes A, Cabanillas F. Sphingosomal vincristine in CHOP is a promising new treatment for Elderly, as well as for poor prognosis patients with aggressive Non-Hodgkins lymphoma (NHL): follow-up results of a phase II study. J Clin Oncol 22(14S):748s, 2004.
110. Goy A, Younes A, McLaughlin P, Pro B, Romaguera J, Hagemeister FB, Fayad L, Trehu EG, Schenkein D, Rodriguez MA. Update on a phase 2 study of bortezomib in patient (pts) with relapsed or refractory indolent or aggressive non-Hodgkin’s lymphomas (NHL). J Clin Oncol 22(14S):577s, 2004.
111. Romaguera J, Cabanillas F, Dang N, Goy A, Fayad L, Hagemeister FB, McLaughlin P, Pro B, Rodriguez MA, Samaniego F, Sarris A, Younes A, Medeiros J, Gagneja GH. Mantle Cell Lymphoma (MCL) – Update on Results After R-HCVAD Without Stem CellTransplant (SCT). . Annals of Oncology 13(2):8, 2002.

Book Chapters

1. Wang M, Zhang L, Ou Z, Sun L, Desai MV, Young KH, Champlin RE, Kwak LW, Romaguera JE. Mantle Cell Lymphoma. In: Hoffman’s Hematology (the sixth edition). In Press.
2. Westin J, Romaguera JE. A Multidisciplinary Approach to Cancer: A Medical Oncologist's View. In: Oncologic Imaging: A Multidisciplinary Approach. Elsevier Saunders: Philadelphia, PA, 13-16, 2012.
3. Romaguera JE, McLaughlin P. Mantle Cell Lymphoma, Chapter 102. In: Williams Hematology, 8th Edition. Ed(s) Kaushansky, Lichtman, Butler, Kipps, Seligsohn, Pechal. McGraw-Hill: Burr Ridge, Illinois, 2010.
4. Frederick WAI, Romaguera JE, Reilly JA, and Grau AM. “Hematologic Malignancies and Splenic Tumors”. In: M.D. Anderson Surgical Oncology Handbook, Fourth Edition. A Lippincott Williams & Wilkins: Philadelphia PA., 464-479, 2006.
5. Frederick WAI, Romaguera JE, Reilly JA, Grau AM. Hematologic Malignancies and Splenic Tumors. In: M.D. Anderson Surgical Oncology Handbook, Third Edition. Lippincott Williams and Wilkins, 2003.

Letters to the Editor

1. Safdar A, Gillenwater AM, Jones DM, Jorgensen JL, Romaguera JE. Rosai-Dorfman disease misdiagnosed as active tuberculosis. Leuk Lymphoma 47(7):1441-2, 7/2006. PMID: 16923590.
2. Oki Y, Copeland A, Hagemeister F, Fayad LE, Fanale M, Romaguera JE, Younes A. Experience with obatoclax mesylate (GX 15-070), a small modecule pan-Bcl-2 family antagonist in patients with relapsed or refractory classical Hodgkin lymphoma. Blood. Submitted.

Manuals, Teaching Aids, Other Teaching Publications

1. Romaguera JE. "Hematology Malignancies: Diagnosis and staging Part II: Lymphoma and Multiple Myeloma". Professional Oncology Education: MDACC, 2013.
2. Romaguera JE, Koeller C. Hematology Course: MDACC, 2008.
3. Romaguera JE. American Society of Hematology (ASH) Teaching Cases – Lymphodemopathy; ASH Case Bank, 2006.
4. Romaguera JE, Huen A. Non-Hodgkin’s Lymphoma Section. Color-Matrix Cancer Staging and Treatment Handbook. Third Edition. 2004.
5. Romaguera JE, Huen A. Non-Hodgkin’s Lymphoma Section. Color-Matrix Cancer Staging and Treatment Handbook. Second edition. 2003.

Grant & Contract Support

Title: An open-label, randomized phase 3 trial of intravenous temsirolimus (CCI-779) at two dose levels compared to investigator's choice therapy, refractory subjects with mantle cell lymphoma
Funding Source: Wyeth-Ayerst Research Laboratories
Role: Principal Investigator
Duration: 2005 - 2011
 
Title: Phase II study of Velcade in subjects with relapsed or refractory mantle cell lymphoma
Funding Source: Millennium Pharmaceuticals
Role: Principal Investigator
Duration: 2003 - 2006
 
Title: Intensive chemotherapy plus rituximab for patients older than 65 years with newly diagnosed mantle cell lymphoma followed by Zevalin for complete responders
Funding Source: MDACC
Role: Principal Investigator
Duration: 2003 - 2004

Last updated: 4/8/2014